Literature DB >> 7591171

Mortality study among workers producing chromate pigments in France.

F Deschamps1, J J Moulin, P Wild, H Labriffe, J M Haguenoer.   

Abstract

In a follow-up study of 294 men who had worked for at least 6 months in a chromate-producing factory in France between 1958 and 1987, only 16 were lost to follow-up and the number of person-years in the study was 5207. Occupational data were provided by the administration of the plant. The causes of deaths were ascertained from hospital and general practitioners' records. The observed numbers of deaths were compared with the expected numbers based on local rates with adjustment for age, sex and calendar time (standardized mortality ratio, SMR). The overall mortality did not differ significantly from that expected (SMR = 1.20, 95% CI = 0.98-1.47), whereas mortality due to lung cancer was in significant excess (SMR = 3.60, 95% CI = 2.13-5.68). Significantly higher lung cancer SMRs were found for workers whose duration of employment was more than 10 years. A non-significant excess was observed for all forms of digestive tract cancer (SMR = 1.30, 95% CI = 0.60-2.47). There were two cases of brain cancer when 0.24 was expected (SMR = 8.44, 95% CI = 1.02-30.49). No previous report has mentioned an association of brain cancer with chromate pigments; however, because of the small numbers involved, a chance excess should be considered.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7591171     DOI: 10.1007/BF00626345

Source DB:  PubMed          Journal:  Int Arch Occup Environ Health        ISSN: 0340-0131            Impact factor:   3.015


  20 in total

1.  Carcinoma of the lung in workmen in the bichromates-producing industry in Great Britain.

Authors:  P L BIDSTRUP; R A CASE
Journal:  Br J Ind Med       Date:  1956-10

2.  Morbidity and mortality experience among chromate workers.

Authors:  H P BRINTON; E S FRASIER; A L KOVEN
Journal:  Public Health Rep       Date:  1952-09       Impact factor: 2.792

3.  A cohort study of bronchial carcinomas in workers producing chromate pigments.

Authors:  S Langård; T Norseth
Journal:  Br J Ind Med       Date:  1975-02

4.  Cancer of the respiratory system in the United States chromate producing industry.

Authors:  W MACHLE; F GREGORIUS
Journal:  Public Health Rep       Date:  1948-08-27       Impact factor: 2.792

Review 5.  Confounding from smoking in occupational epidemiology.

Authors:  O Axelson
Journal:  Br J Ind Med       Date:  1989-08

6.  Mortality in chromium chemical production workers: a prospective study.

Authors:  R B Hayes; A M Lilienfeld; L M Snell
Journal:  Int J Epidemiol       Date:  1979-12       Impact factor: 7.196

7.  Occurrence of lung cancer in workers producing chromium pigments.

Authors:  S Langård; T Vigander
Journal:  Br J Ind Med       Date:  1983-02

8.  Aspects on confounding in occupational health epidemiology.

Authors: 
Journal:  Scand J Work Environ Health       Date:  1978-03       Impact factor: 5.024

9.  Lung-cancer mortality of workers making chrome pigments.

Authors:  J M Davies
Journal:  Lancet       Date:  1978-02-18       Impact factor: 79.321

10.  Health of workmen in the chromate-producing industry in Britain.

Authors:  M R Alderson; N S Rattan; L Bidstrup
Journal:  Br J Ind Med       Date:  1981-05
View more
  10 in total

1.  Epigallocatechin-3-gallate (EGCG) protects against chromate-induced toxicity in vitro.

Authors:  Fen Wu; Hong Sun; Thomas Kluz; Hailey A Clancy; Kathrin Kiok; Max Costa
Journal:  Toxicol Appl Pharmacol       Date:  2011-11-04       Impact factor: 4.219

Review 2.  Exposure to Trace Elements and Risk of Skin Cancer: A Systematic Review of Epidemiologic Studies.

Authors:  Natalie H Matthews; Katherine Fitch; Wen-Qing Li; J Steven Morris; David C Christiani; Abrar A Qureshi; Eunyoung Cho
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-10-08       Impact factor: 4.254

3.  The intracellular redox stress caused by hexavalent chromium is selective for proteins that have key roles in cell survival and thiol redox control.

Authors:  Judith M Myers; William E Antholine; Charles R Myers
Journal:  Toxicology       Date:  2011-01-13       Impact factor: 4.221

4.  Oxidative stress-related lung dysfunction by chromium(VI): alleviation by Citrus aurantium L.

Authors:  Nejla Soudani; Moez Rafrafi; Ibtissem Ben Amara; Ahmed Hakim; Afef Troudi; Khaled Mounir Zeghal; Hichem Ben Salah; Tahia Boudawara; Najiba Zeghal
Journal:  J Physiol Biochem       Date:  2012-09-13       Impact factor: 4.158

5.  The pro-oxidant chromium(VI) inhibits mitochondrial complex I, complex II, and aconitase in the bronchial epithelium: EPR markers for Fe-S proteins.

Authors:  Charles R Myers; William E Antholine; Judith M Myers
Journal:  Free Radic Biol Med       Date:  2010-09-27       Impact factor: 7.376

Review 6.  The effects of chromium(VI) on the thioredoxin system: implications for redox regulation.

Authors:  Charles R Myers
Journal:  Free Radic Biol Med       Date:  2012-04-18       Impact factor: 7.376

7.  Reduction of hexavalent chromium by human cytochrome b5: generation of hydroxyl radical and superoxide.

Authors:  Griselda R Borthiry; William E Antholine; B Kalyanaraman; Judith M Myers; Charles R Myers
Journal:  Free Radic Biol Med       Date:  2006-12-15       Impact factor: 7.376

8.  Reductive activation of hexavalent chromium by human lung epithelial cells: generation of Cr(V) and Cr(V)-thiol species.

Authors:  Griselda R Borthiry; William E Antholine; Judith M Myers; Charles R Myers
Journal:  J Inorg Biochem       Date:  2008-01-08       Impact factor: 4.155

9.  The effects of hexavalent chromium on thioredoxin reductase and peroxiredoxins in human bronchial epithelial cells.

Authors:  Judith M Myers; Charles R Myers
Journal:  Free Radic Biol Med       Date:  2009-08-22       Impact factor: 7.376

10.  Hexavalent chromium causes the oxidation of thioredoxin in human bronchial epithelial cells.

Authors:  Judith M Myers; William E Antholine; Charles R Myers
Journal:  Toxicology       Date:  2008-02-02       Impact factor: 4.221

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.